Fritextsökning
Artiklar per år
Innehållstyper
-
Ny chefredaktör på Biotech Sweden
Det är nu klart vem som kommer att efterträda Loth Hammar som chefredaktör. Han anländer från USA i slutet av sommaren.
-
Ledarbyte på Biotech Sweden
Chefredaktören för Nordens största nyhetstjänst inom life science går vidare till en helt ny bransch.
-
Innate Pharmaceuticals byter namn
Creative Antibiotics vill bolaget istället heta.
-
Sverige populärast på BIO2009
Rekordmånga besökare kom for att höra Jonas Frisén från Karolinska Institutet berätta om svensk stamcellsforskning.
-
Hallå där, Peter Bramberg ...
... ny chef för life science vid Invest in Sweden Agency, ISA.
-
Hallå där, Örjan Norberg
...nytillträdd vd för Umeå Biotech Incubator - det händer en massa spännande i Umeå just nu, berätta!
-
Nätspel lär idrottare vägra doping
En forskare vid Köpenhamns universitet får pengar från internationell antidopingkommitté, för ett nytt grepp att stoppa idrottsfusk.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Crafoord Prize to an American and two Japanese
Today the Royal Swedish Academy of Sciences announces the laureates of the Crafoord Prize in Polyarthritis 2009.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Prenatal testing breakthrough
For the first time specific gene expression information from fetal cells isolated from maternal blood samples is available.
-
New influenza vaccine to EU
The Astrazeneca subsidary Medimmune submits marketing authorisationapplication in EU for an new intranasal vaccine against influenza.
-
Academy for a new turn at work
Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.
-
Fat cells' reaction differs with body weight
The fat cells of overweight people may react differently to dietary changes than in their lean peers, according to a pioneering study from the Dutch organization TNO Quality of Life.
-
New tools to fight bacteria
Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antibiotic-resistant bacteria. That is stated in a report commissioned by the Swedish government.